The case for & against
Bull & Bear analysis
Bullish
Exact Sciences Corporation (NASDAQ: EXAS) is a leading biotechnology firm that specializes in non-invasive cancer diagnostics, particularly in colorectal cancer screening through its flagship product, Cologuard. The company has positioned itself as an innovator in the oncology diagnostics field, expanding its offerings with product line extensions such as CancerGuard and OncoDetect. Exact Sciences stands to capitalize on the rising demand for effective cancer screening solutions in a healthcare landscape increasingly focused on preventative measures.
Bull says
- ↑Q3 2025 revenue up 20% YoY to $851 M; screening revenue grew 22% to $666 M
- ↑Cologuard Plus launch offers 95% cancer sensitivity and 94% specificity
- ↑200k+ providers order Cologuard; five of top ten payers cover Plus
- ↑$1 B+ cash on hand and $190 M free cash flow fund growth
- ↑2025 guidance of $3.22–$3.235 B implies ~14% revenue growth and wider EBITDA margins
- ↑Strong commercial momentum and strategic partnerships underpin expansion
Bear says
- ↓Care gap shipment swings could compress gross margins
- ↓New blood-based screening tests may erode pricing power and share
- ↓Heavy reliance on payer coverage and approvals risks launch delays
- ↓Execution uncertainty persists after mixed adoption trends for new products
- ↓External regulatory changes and market volatility could disrupt operations
- ↓Margin pressure from care gap initiatives and competition warrants caution
Investment themes with EXAS
Demographics: Elderly Care↓ -0.50%
Services and products for aging population
UCB.BR · JNJ · AZN
Earnings Call · Q3 2024 · Mgmt. Guidance
Updated 09-07-2026neutral
Transcript signals
Bull points
- we would estimate that the addressable opportunity is between 4 and 5 million completed FIT tests per year.
- we've already demonstrated the ability to double that compliance rate. And we'd obviously look to double from the roughly 22% we're at today. And so if you kind of get this even to the 40% to 50% level Kevin talked about, you adjust for interval and apply our Cologuard average sale price. This is a multi-billion dollar opportunity for us over time. And we're really, really excited to go after it.
- this is a really great source of revenue for us. It's obviously highly predictable, recurring, high margin revenue. Last year we disclosed that represented roughly 20% of screening revenue in 2023. We're at 25% now here in the back half of the year.
Bear points
- we just didn't see the increases aaron mentioned that we typically would see at that time of year so when did we know that there was going to be a challenge that really starting in September and into October we realized that there was a greater challenge there than we had seen in past falls during that time period of the year, which we have described as typically the steepest increase.
- We know that this is disappointing to you, to investors, we're confident in our ability to grow and achieve or exceed our long-range plan as we've laid out.
- Excluding care gap programs, since August, Cologuard orders have grown below the historical rate, which our prior guidance assumed.
Read full transcript analysis ›